PhosPrint develops laser-induced forward transfer bioprinting systems that print autologous cells directly onto tissue during surgery rather than ex vivo. Its lead programme, InvivoLPrint-U, targets bladder reconstruction for cancer patients undergoing cystectomy and has completed preclinical porcine studies. The company is led by Prof. Ioanna Zergioti with co-founder Dr Apostolos Klinakis and is based at the Lefkippos Technology Park at NCSR Demokritos. Headquartered in Athens.